Switching from EFV/TDF/3TC to B/F/TAF or DTG/3TC in virologically suppressed PLWH shows no significant between-group metabolic differences over 24 months.
Switching HIV drugs showed similar metabolic changes over two years in this real-world study.
This retrospective real-world study evaluated 326 virologically suppressed persons with HIV (PLWH) switching from efavirenz/tenofovir disopr…
Switching HIV drugs caused similar weight gain and metabolic shifts over two years, meaning lifestyle factors matter more than the specific …
Nevirapine plus lamivudine and zidovudine improved lymphocyte counts and reduced adverse effects versus efavirenz in HIV patients.
New HIV drug combo showed fewer side effects and better immune markers in small trial
This randomized controlled trial enrolled 100 patients with HIV/AIDS in a hospital setting. Participants received either lamivudine plus zid…
A new HIV drug combo boosted immune cells and caused fewer side effects than the standard alternative in a recent trial.